B+
Bull case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-11-05 · RankAlpha Sentiment Codex
PRGO
PerrigoANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q3 adjusted EPS of $0.60 exceeded the $0.55 estimate cited by Investing.com, while store-brand share gains and a simpler portfolio could eventually improve returns. The sale's expected benefits are not yet realized.
Posture
Constructive
Lead driver
Value
What changed
4 setup hits (3d) with net bullish as of 2026-11-05.
What can break
At September 26, cash was $437 million against $3.3 billion of total debt; the outlook assumes net leverage of approximately 4.0 times adjusted EBITDA. [#SEC-8K-2026-11-04]
Momentum
95
Value
54
Sentiment
54
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $16.50 · Bull $19.00 · Bear $12.00Analysis 2026-11-05; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-11-05 • Vendor: Data Vendor v1
Scores
As of 2026-11-05 • Model: HYBRID_IC_RP
AI Memo
As of 2026-11-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-11-05
Investment thesis
As of 2026-11-05
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-11-05. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $17.00
Why
Momentum95 · Δ7d -6.7
Value54 · Δ7d -0.1
Sentiment54 · Δ7d -
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 4 setup hits (3d) with net bullish as of 2026-11-05.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • At September 26, cash was $437 million against $3.3 billion of total debt; the outlook assumes net leverage of approximately 4.0 times adjusted EBITDA. [#SEC-8K-2026-11-04]
- • Q3 Core adjusted gross margin fell 140 basis points and adjusted operating margin fell 210 basis points year over year. [#SEC-8K-2026-11-04]
- • Sales of $989 million were below Investing.com's roughly $1 billion consensus figure, and the lower Core outlook, declining organic sales and weaker margins challenge the turnaround.
Catalyst clock
2026-12-31
Lower core outlook offsets the quarterly EPS beat
Lead driver: Value · See fundamentals
Momentum
95
18% active weight
Current posture
7d trendSoftening
Δ7d
-6.7
Δ21d
-3.8
Value
54
43% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
54
39% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 94.7 / Value 54.2 / Sentiment 53.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-11-05. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$16.50
Analysis reference price unavailable
Analysis 2026-11-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-11-05 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-11-05
Fundamentals (TTM)
As of 2026-11-05
Market Cap
$2.18B
Beta
0.39
Shares Out
138.77M
P/E (TTM) · Derived
-1.5
P/S (TTM)
0.46
P/FCF (TTM)
17.35
Rev YoY
-3.2%
EPS YoY
-977.8%
Gross Margin
+33.3%
Op Margin
+6.4%
Net Debt
$3.29B
Current Ratio
2.32
As of 2026-11-05 • Updated nightlySource: Internal modelMethods & Data